PATHOLOGY CODES AND LABORATORY CPT CODE GUIDELINES
Revised Codes
80162 Digoxin; total
80164 Valproic acid (dipropylacetic acid); total
80171 Gabapentin, whole blood, serum, or plasma
80299 Quantitation of therapeutic drug, not elsewhere specified
81245 FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; internal tandem duplication (ITD) variants (ie, exons 14, 15)
81402 Molecular pathology procedure, Level 3 (eg, >10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants of 1 exon, loss of heterozygosity [LOH], uniparental disomy [UPD])
81403 Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons) 
81404 Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis)
81405 Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication / deletion variants of 11-25 exons, regionally targeted cytogenomic array analysis)
82541 Column chromatography/mass spectrometry (eg, GC/MS, or HPLC/MS), non-drug analyte not elsewhere specified; qualitative, single stationary and mobile phase
82542 ; quantitative, single stationary and mobile phase
82543 ; stable isotope dilution, single analyte, quantitative, single stationary and mobile phase
82544 ; stable isotope dilution, multiple analytes, quantitative, single stationary and mobile phase
84600 Volatiles (eg, acetic anhydride, diethylether)
86900 Blood typing, serologic; ABO
86901 ; Rh (D)
86902 ; antigen testing of donor blood using reagent serum, each antigen test
86904 ; antigen screening for compatible unit using patient serum, per unit screened
86905 ; RBC antigens, other than ABO or Rh (D), each
86906 ; Rh phenotyping, complete
87501 Infectious agent detection by nucleic acid (DNA or RNA); influenza virus, includes reverse transcription, when performed  and amplified probe technique, each type or subtype
87502 ; influenza virus, for multiple types or sub-types, includes multiplex reverse transcription and multiplex amplified probe technique, first 2 types or sub-types
87503 ; influenza virus, for multiple types or sub-types, includes multiplex reverse transcription and multiplex amplified probe technique, each additional influenza virus type or sub-type beyond 2 (List separately in addition to code for primary procedure)
87631 Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets
87632 ; respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets
87633 ; respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets
88342 Immunohistochemistry or immunocytochemistry, specimen; initial single antibody stain procedure
88360 Morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen, each single antibody stain procedure; manual
88361 ; using computer-assisted technology
88365 In situ hybridization (eg, FISH), per specimen; initial single probe stain procedure
88367 Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), using computer-assisted technology, per specimen; initial single probe stain procedure
88368 Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; initial single probe stain procedure
New Codes
80162 Digoxin; free
80165 Valproic acid (dipropylacetic acid); free
80300 Drug screen, any number of drug classes from Drug Class List A; any number of non-TLC devices or procedures, (eg, immunoassay) capable of being read by direct optical observation, including instrumented-assisted when performed (eg, dipsticks, cups, cards, cartridges), per date of service
80301 ; single drug class method, by instrumented test systems (eg, discrete multichannel chemistry analyzers utilizing immunoassay orenzyme assay), per date of service
80302 Drug screen, presumptive, single drug class from Drug Class List B, by immunoassay (eg, ELISA) or non-TLC chromatography without mass spectrometry (eg, GC, HPLC), each procedure
80303 Drug screen, any number of drug classes, presumptive, single or multiple drug class method; thin layer chromatography procedure(s) (TLC) (eg, acid, neutral, alkaloid plate), per date of service
80304 ; not otherwise specified presumptive procedure (eg, TOF, MALDI, LDTD, DESI, DART), each procedure
80320 Alcohols
80321 Alcohol biomarkers; 1 or 2
80322 ; 3 or more
80323 Alkaloids, not otherwise specified
80324 Amphetamines; 1 or 2
80325 ; 3 or 4
80326 ; 5 or more
80327 Anabolic steroids; 1 or 2
80328 ; 3 or more
80329 Analgesics, non-opioid; 1 or 2
80330 ;3-5
80331 ; 6 or more
80332 Antidepressants, serotonergic class; 1 or 2
80333 ; 3-5
80334 ; 6 or more
80335 Antidepressants, tricyclic and other cyclicals; 1 or 2
80336 ; 3-5
80337 ; 6 or more
80338 Antidepressants, not otherwise specified
80339 Antiepileptics, not otherwise specified; 1-3
80340 ; 4-6
80341 ; 7 or more
80342 Antipsychotics, not otherwise specified; 1-3
80343 ; 4-6
80344 ; 7 or more
80345 Barbiturates
80346 Benzodiazepines; 1-12
80347 ; 13 or more
80348 Buprenorphine
80349 Cannabinoids, natural
80350 Cannabinoids, synthetic; 1-3
80351 ; 4-6
80352 ; 7 or more
80353 Cocaine
80354 Fentanyl
80355 Gabapentin, non-blood
80356 Heroin metabolite
80357 Ketamine and norketamine
80358 Methadone
80359 Methylenedioxyamphetamines (MDA, MDEA, MDMA)
80360 Methylphenidate
80361 Opiates, 1 or more
80362 Opioids and opiate analogs; 1 or 2
80363 ; 3 or 4
80364 ; 5 or more
80365 Oxycodone
80366 Pregabalin
80367 Propoxyphene
80368 Sedative hypnotics (non-benzodiazepines)
80369 Skeletal muscle relaxants; 1 or 2
80370 ; 3 or more
80371 Stimulants, synthetic
80372 Tapentadol
80373 Tramadol
80374 Stereoisomer (enantiomer) analysis, single drug class
80375 Drug(s) or substance(s), definitive, qualitative or quantitative, not otherwise specified; 1-3
80376 ; 4-6
80377 ; 7 or more
81246 FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis, internal tandem duplication (ITD) variants (ie, exons 14, 15); tyrosine kinase domain (TKD) variants (eg, D835, I836)
81288 MLH1 (mutL homolog 1, colon cancer, non-polyposis type 1)(eg. Hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; promoter methylation analysis
81313 PCA3/KLK3 (prostate cancer antigen 3 [non-protein  coding]/ kallikrein-related peptidase 3[prostate specific antigen]) ratio (eg, prostate cancer)
81410 Aortic dysfunction or dilation (eg, Marfan syndrome, Loeys Dietz syndrome, Ehler Danlos syndrome type IV, arterial tortuosity syndrome); genomic sequence analysis panel, must include sequencing of at least 9 genes, including FBN1, TGFBR1, TGFBR2, COL3A1, MYH11, ACTA2, SLC2A10, SMAD3, and MYLK
81411 ; duplication/deletion analysis panel, must include analyses for TGFBR1, TGFBR2, MYH11, and COL3A1 
81415 Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis
81416 ; sequence analysis, each comparator exome (eg, parents, siblings) (List separately in addition to code for primary procedure)
81417 ; re-evaluation of previously obtained exome sequence (eg, updated knowledge or unrelated condition/syndrome)
81420 Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21
81425 Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis
+81426 ; sequence analysis, each comparator genome (eg, parents, siblings) (List separately in addition to code for primary procedure)
81427 ; re-evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome)
81430 Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); genomic sequence analysis panes, must include sequencing of at least 60 genes, including CDH23, CLRN1, GJB2, GPR98, MTRNR1, MY07A, MY015A, PCDH15, OTOF, SLC26A4, TMC1, TMPRSS3, USH1C, USH1G, USH2A, and WFS1
81431 ; duplication/deletion analysis panel, must include copy number analyses for STRC and DFNB1 deletions in GJB2 and GJB6 genes
81435 Hereditary colon cancer syndromes (eg, Lynch syndrome, familial adenomatosispolyposis); genomic sequence analysis panel, must include analysis of at least 7 genes,including APC, CHEK2, MLH1, MSH2, MSH6, MUTYH, and PMS2
81436 ; duplication/delation gene analysis panel, must include analysis of at lease 8 genes, including APC, MLH1, MSH2, MSH6, PMS2, EPCAM, CHEK2, and MUTYH
81440 Nuclear encoded mitochondrial genes(eg, neurologic or myopathic phenotypes),genomic sequence panel, must include analysis of at least 100 genes, including BCS1L, C10orf2, COX10, DGU0K, MPV17, OPA1m PDSS2, POLG, POLG2, RRM2B, SC01, SC02, SLC25A4, SUCLA2, SUCLG1, TAZ, TK2, and TYMP
81445 Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS,MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copynumber variants or rearrangements, if performed
81450 Targeted genomic sequence analysis panel, hematolymphoid neoplasm, or disorder, DNA and RNA analysis when  performed, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KRAS, KIT, MLL, NRAS, NPM1, NOTCH1), interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed
81455 Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm, DNA and RNA analysis when performed, 51 or greater genes (eg, ALK, BRAF, CDKN2A, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NPM1, NRAS, MET, NOTCH1, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RE1), interrogation for sequence variants and copy number variants or rearrangements, if performed
81460 Whole mitochondrial genome (eg, Leigh syndrome, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes {MELAS}, myoclonic epilepsy with ragged-red fibers [MERFF], leber hereditary optic neuropathy [LHON]), GENOMIC SEQUENCE, MUST INCLUDE SEQUENCE ANALYSIS OF ENTIRE MITOCHONDRIAL GENOME WITH HETEROPLASMY DETECTION
81465 Whole mitochondrial genome large deletion analysis panel (eg, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia), including heteroplasmy detection, if performed
81470 X-linked intellectual disability (XLID) (eg, syndromic and non-syndromic XLID); genomic sequence analysis panel, must include sequencing of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2
81471 Duplication/deletion gene analysis, must include analysis of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2
81519 Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin embedded tissue, algorithm reported as recurrence score
83006 Growth stimulation expressed gene 2(ST2, Interleukin 1 receptor like-1)
87505 Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets
87506 ; gastrointestinal pathogen (eg, clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), included multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets
87507 ; gastrointestinal pathogen (eg, clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), included multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets
87623 Human Papillomavirus (HPV), low-risk types (eg, 6, 11, 42, 43, 44
87624 Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68)
87625 Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed
87806 HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies
+88341 Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)
88344 Immunohistochemistry or immunocytochemistry, per specimen; each multiplex antibody stain procedure
88364 In situ hybridization (eg, FISH), per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure)
88366 In situ hybridization (eg, FISH), per specimen; each multiplex probe stain procedure
+88373 Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), using computer-assisted technology, per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure)
88374 ; each multiplex probe stain procedure
+88369 Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure)
88377 ; each multiplex probe stain procedure
89337 Cryopreservation, mature oocyte(s)
Deleted Codes
80100 Drug screen, qualitative; multiple drug classes chromatographic method, each procedure
80101 Drug screen, qualitative; single drug class method (eg, immunoassay, enzyme assay), each drug class
80102 Drug confirmation, each procedure
80103 Tissue preparation for drug analysis
80104 Drug screen, qualitative; multiple drug classes other than chromatographic method, each procedure
80152 Amitriptyline
80154 Benzodiazepines
80160 Desipramine
80166 Doxepin
80172 Gold
80174 Imipramine
80182 Nortriptyline
80196 Salicylate
80440 Thyrotropin releasing hormone (TRH) stimulation panel; for hyperprolactinemia This panel must include the following: Prolactin (84146 x 3)
82000 Acetaldehyde, blood
82003 Acetaminophen
82055 Alcohol (ethanol); any specimen except breath
82101 Alkaloids, urine, quantitative
82145 Amphetamine or methamphetamine
82205 Barbiturates, not elsewhere specified
82520 Cocaine or metabolite
82646 Dihydrocodeinone
82649 Dihydromorphinone
82651 Dihydrotestosterone (DHT)
82654 Dimethadione
82666 Epiandrosterone
82690 Ethchlorvynol
82742 Flurazepam
82953 Glucose; tolbutamide tolerance test
82975 Glutamine (glutamic acid amide)
82980 Glutethimide
83008 Guanosine monophosphate (GMP), cyclic
83055 Hemoglobin; sulfhemoglobin, qualitative
83071 Hemosiderin; quantitative
83634 Lactose, urine; quantitative
83805 Meprobamate
83840 Methadone
83858 Methsuximide
83866 Mucopolysaccharides, acid; screen
83887 Nicotine
83952 Opiate(s), drug and metabolites, each procedure
84022 Phenothiazine
84127 Porphyrins, feces; qualitative
87001 Animal inoculation, small animal; with observation
87620 Infectious agent detection by nucleic acid (DNA or RNA); papillomavirus, human, direct probe technique
87621 Infectious agent detection by nucleic acid (DNA or RNA); papillomavirus, human, amplified probe technique
87622 Infectious agent detection by nucleic acid (DNA or RNA); papillomavirus, human, quantification
88343 Immunohistochemistry or immunocytochemistry, each separately identifiable antibody per block, cytologic preparation, or hematologic smear; each additional separately identifiable antibody per slide (List separately in addition to code for primary procedure)
88349 Electron microscopy; scanning